Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4670-4679

  Spinella, Francesca ^a   Rosanò, Laura ^a   Di Castro, Valeriana ^a   Nicotra, Maria Rita ^b   Natali, Pier Giorgio ^a   Bagnato, Anna ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIN A RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN E2; PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CARCINOMA CELL; CELL INVASION; CELL PROTECTION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MITOGENESIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ENDOTHELIN-1; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOMETHACIN; ISOENZYMES; LUCIFERASES; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MICE, NUDE; NITROBENZENES; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3242741855     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0315     Document Type: Article

References (47)

1. Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 2002;20:1161-3.
2. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:994-9.
3. Bagnato A, Tecce R, Moretti C, et al. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1995;1:1059-66.
4. Bagnato A, Salani D, Di Castro V, et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 1999;59:720-7.
5. Egidy G, Juillerat-Jeanneret L, Jeannin JF, et al. Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol 2000;157:1863-74.
6. Venuti A, Salani D, Manni V, Poggiali F, Bagnato A. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J 2000;14:2277-83.
7. Baley PA, Resink TJ, Eppenberger U, Hahn AW. Endothelin messenger RNA and receptors are differentially expressed in cultured human breast epithelial and stromal cells. J Clin Investig 1990;85:1320-3.
8. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 1999;96:11496-500.
9. Bagnato A, Rosanò L, Di Castro V, et al. Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am J Pathol 2001;158:841-7.
10. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1999;46:325-414.
11. Nelson JB, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
12. Bagnato A, Tecce R, Di Castro V, Catt KJ. Activation of mitogenic signaling by endothelin-1 in ovarian carcinoma cells. Cancer Res 1997;57:1306-11.
13. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel- induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002;61:524-32.
14. Rosanò L, Varmi M, Salani D, et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 2001;61:8340-6.
15. Salani D, Di Castro V, Nicotra MR, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157:1537-47.
16. Salani D, Taraboletti G, Rosanò L, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 2000;157:1703-11.
17. Spinella F, Rosanò L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J Biol Chem 2002;277:27850-5.
18. Spinella F, Rosanò L, Di Castro V, et al. Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem 2003;278:41294-301.
19. Rosanò L, Spinella F, Salani D, et al. Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma. Cancer Res 2003;63:2447-53.
20. Pratt PF, Bokemeyer D, Foschi M, Sorokin A, Dunn MJ. Alterations in subcellular localization of p38 MAPK potentiates endothelin-stimulated COX-2 expression in glomerular mesangial cells. J Biol Chem 2003;278:51928-36.
21. Windischhofer W, Zach D, Fauler G, et al. Involvement of Rho and p38 MAPK in endothelin-1-induced expression of PGHS-2 mRNA in osteoblast-like cells. J Bone Miner Res 2002;17:1774-84.
22. Rebsamen MC, Capoccia R, Vallotton MB, Lang U. Role of cyclooxygenase 2, p38 and p42/44 MAPK in the secretion of prostacyclin induced by epidermal growth factor, endothelin-1 and angiotensin II in rat ventricular cardiomyocytes. J Mol Cell Cardiol 2003;35:81-9.
23. Chen D, Balyakina EV, Lawrence M, Christman BW, Meyrick B. Cyclooxygenase is regulated by ET-1 and MAPKs in peripheral lung microvascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003;284:L614-21.
24. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
25. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
26. Klimp AH, Hollema H, Kempinga C, et al. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 2001;61:7305-9.
27. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 2001;8:31-6.
28. Landen CN Jr, Mathur SP, Richardson MS, Creasman WT. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol 2003;188:1174-6.
29. Shigemasa K, Tian X, Gu L, et al. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 2003;22:99-105.
30. Denkert C, Kobel M, Pest S, et al. Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002;160:893-903.
31. Erkinheimo TL, Lassus H, Finne P, et al. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 2004;10:538-45.
32. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002;13:1205-11.
33. Gupta RA, Tejada LV, Tong BJ, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003;63:906-11.
34. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000;60:5310-7.
35. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 2000;275:33951-6.
36. Guo YS, Cheng JZ, Jin GF, et al. Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of the epidermal growth factor receptor. J Biol Chem 2002;277:48755-63.
37. Sheng H, Shao J, Dixon DA, et al. Transforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000;275:6628-35.
38. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
39. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
40. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature (Lond) 1996;379:557-60.
41. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature (Lond) 1999;402:884-8.
42. Luttrell LM, Ferguson SS, Daaka Y, et al. β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes. Science (Wash DC) 1999;283:655-61.
43. 1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 2003;22:8653-61.
44. Erkinheimo TL, Lassus H, Sivula A, et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 2003;63:7591-4.
45. Denkert C, Weichert W, Pest S, et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004;64:189-95.
46. Han JA, Kim J, Ongusaha PP, et al. p53-mediated induction of COX-2 counteracts p53- or genotoxic-induced apoptosis. EMBO J 2002;21:5635-44.
47. Nishihara H, Kizaka-Kondoh S, Insel PA, Eckmann L. Inhibition of apoptosis and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci USA 2003;100:8921-6.